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Primary biliary cholangitis (PBC) is a rare chronic cholestatic liver disease that may progress to biliary cirrhosis if left
untreated. The ﬁrst-line therapy for PBC is ursodeoxycholic acid (UDCA). Unfortunately, 1 of 3 patients does not
respond to UDCA. These patients are at risk for developing clinical events, including cirrhosis, complications of portal
hypertension, hepatocellular carcinoma, liver transplant, or death. Recently, the U.S. Food and Drug Administration
approved obeticholic acid to be used in certain patients with PBC. Off-label therapies are also used, and several other
therapies are currently under evaluation. Real-world effectiveness of newly approved and off-label therapies remains
unknown. TARGET-PBC is a 5-year, longitudinal, observational study of patients with PBC that will evaluate the effec-
tiveness of clinical practice interventions and provide practical information unobtainable in registration trials. Enrollment
will take place at both academic and community sites. In addition to consenting to medical records review, participants
will be asked to provide an annual blood sample and complete patient reported outcome surveys at predetermined intervals.
Any available liver biopsies will be digitally preserved. Conclusion: Key study outcomes will be the evaluation of the safety
and effectiveness of PBC interventions and the assessment of disease progression under real-world conditions. (Hepatology
Communications 2018;2:484-491)
Primary biliary cholangitis (PBC), formerlycalled primary biliary cirrhosis, is an uncom-mon chronic cholestatic liver disease character-
ized by progressive inﬂammation and destruction of
the interlobular bile ducts, ultimately leading to the
development of biliary cirrhosis. The incidence across
Europe, North America, Asia, and Australia has been
estimated to range from 0.9 to 5.8 per 100,000 people,
with a prevalence range from 1.91 to 40.20 per
100,000 people.(1) Approximately 130,000 individuals
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in the United States may have the disease.(2) PBC
most often affects middle-aged women and can signiﬁ-
cantly diminish their quality of life by causing symp-
toms such as pruritus and fatigue as well as leading to
liver failure. The natural history of untreated PBC is
one of slow progression toward cirrhosis, with median
survival without liver transplantation ranging from 10
to 15 years.(3)
Ursodeoxycholic acid (UDCA), approved by the U.S.
Food and Drug Administration (FDA) in 2004 as a
ﬁrst-line therapy for PBC, is a hydrophilic bile acid,
and most published therapeutic trials on its use in
patients with PBC have shown positive effects on bio-
chemical parameters and histologic variables.(4) Speciﬁ-
cally, at a dose of 13-15 mg/kg/day, UDCA has been
shown to improve biochemical liver tests, delay develop-
ment of ﬁbrosis, delay the rate of development of
esophageal varices, and prolong survival without liver
transplantation in patients with PBC.(5,6) Deﬁnitions of
biochemical response to therapy have continued to be
proposed and to evolve (Table 1).(3) The GLOBE score
is a validated risk calculation developed by the Global
PBC Study Group that reliably predicts response to
UDCA using ﬁve objective variables (age, bilirubin,
albumin, alkaline phosphatase [ALP], and platelet
count). Comparison to a similar age-matched control
population allows identiﬁcation of patients for whom
monotherapy with UDCA is inadequate and who will
beneﬁt most from new therapies. The ALP and total
bilirubin values in particular show strong predictive sig-
niﬁcance. The GLOBE score predicts prognosis (sur-
vival and transplant-free survival) of patients who have
been treated with UDCA for 1 year, regardless of their
disease stage, and helps to direct therapeutic deci-
sions.(7) Transplant-free survival can also be accurately
calculated using the GLOBE score with laboratory val-
ues collected 2-5 years after UDCA treatment. Impor-
tantly, the GLOBE PBC risk score was also validated
in patients who were not taking UDCA.
Regardless of the classiﬁcation and scoring systems,
up to 40% of treated patients fail to reach biochemical
response to UDCA. Poor biochemical response clearly
correlates with diminished survival and need for liver
transplantation. Developing an alternative medical
strategy for incomplete responders is therefore of
utmost importance.
A variety of other drugs have been studied in PBC
with little or no added beneﬁt to UDCA. These have
included immunosuppressants, immunomodulators,
antiﬁbrotics, antioxidants, antibiotics, and even antivi-
rals. Budesonide and ﬁbrates are under investigation as
additional treatment options. In patients with incom-
plete response to UDCA (13-15 mg/kg/day), the addi-
tion of 160 mg of daily fenoﬁbrate has been found to
further biochemical improvement in terms of serum
ALP, aspartate aminotransferase. and immunoglobulin
M levels.(3) Fenoﬁbrate has been used as off-label
treatment for PBC. Likewise, the recent randomized
controlled study of bezaﬁbrate in combination with
UDCA in primary biliary cirrhosis (BEZURSO) trial
showed that bezaﬁbrate led to normalization of serum
ALP in 67% of PBC patients with inadequate
response to UDCA.(8) This medication, however, is
not available in the United States.
Obeticholic acid (6-alpha-ethyl-chenodeoxycholic
acid; OCA) is a farnesoid X receptor agonist and is the
second FDA-approved treatment for PBC. The phase
III PBC OCA International Study of Efﬁcacy
(POISE) demonstrated that 12 months of OCA,
administered either as adjuvant to UDCA or alone,
resulted in improvements in ALP, total bilirubin, and
other biochemical markers of disease.(9) Subsequently,
in May 2016, the FDA approved OCA to be used in
combination with UDCA for patients with PBC and
an incomplete response to UDCA or as monotherapy
for those who are intolerant to UDCA.(10)
Importantly, phase III clinical trials are performed
in highly selected adherent study participants who may
ARTICLE INFORMATION:
From the 1Department of Medicine, University of Miami, Miami, FL; 2University of California Davis, Davis, CA; 3Department of
Transplantation, Mayo Clinic, Phoenix, AZ; 4TARGET PharmaSolutions, Inc., Chapel Hill, NC; 5University of Texas Southwestern
Medical Center, Dallas, TX; 6Stanford University, Stanford, CA; 7University of North Carolina, Chapel Hill, NC.
ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:
Cynthia Levy, M.D.
Associate Professor of Medicine, University of Miami
1500 NW 12th Avenue, Suite 1101
Miami, FL 33136
E-mail: clevy@med.miami.edu
Tel: 11-305-243-2330
HEPATOLOGY COMMUNICATIONS, Vol. 2, No. 5, 2018 LEVY ET AL.
485
lack signiﬁcant comorbidities outside the disease area in
question. This has been the case in several areas within
hepatology.(11) These trials are good measures of clinical
efﬁcacy; however, the more germane question for clini-
cians and their patients is one of real-world effective-
ness. Conﬁrming the safety and effectiveness of
interventions under real-world conditions and establish-
ing pragmatic methods of assessing disease diagnosis
and progression are critical for developing appropriate
clinical practice guidelines. This assessment can only be
made in postmarketing surveillance when new medica-
tions are incorporated into general practice among
patients with multiple comorbidities and variable levels
of treatment compliance. Ongoing monitoring of side-
effect proﬁles of these emerging therapeutic agents for
PBC and determination of whether proposed manage-
ment plans within clinical trial protocols are effective in
mitigating adverse events in clinical practice are essential
for guiding policies on PBC management.
TARGET-PBC is a cooperative consortium of
principal investigators from both academic institutions
and community sites that treat patients with PBC. It
will provide unique opportunities to engage networked
physician teams in evidence-based evaluation of
PBC therapies and to involve these teams in clinical
research. This collaboration of expertise and the
information gathered from specimen-banking high-
throughput technologies and biomedical informatics
will allow investigators to analyze data at a variety of
levels, from subsets to very large populations.
Patients and Methods
OVERVIEW
TARGET-PBC is a 5-year, longitudinal, observa-
tional study that will describe the real-world practice of
diagnosis, management, and natural history of PBC.
The overarching aim of TARGET-PBC is to demon-
strate the clinical effectiveness of PBC therapies in a
real-world setting. It uses standardized data collection
tools and follows a detailed protocol to increase the
efﬁciency and minimize costs associated with perform-
ing clinical research, while ensuring collection of criti-
cal safety and efﬁcacy data on prescribed PBC
therapies. Adult (18 years old) patients being man-
aged or treated for PBC are included. Up to 1,500
adults with PBC will be enrolled. Current participating
patients are from academic (n 5 16) and community
(n 5 2) gastroenterology and hepatology practices and
represent a national distribution (Fig. 1). Patient man-
agement will follow each site’s local standard of care,
and no speciﬁc treatments, clinical assessments, or lab-
oratory tests will be dictated by enrollment in the
study. Site recruitment is ongoing. Central and/or local
institutional review board (IRB) approvals are obtained
prior to patient enrollment. The entire study will be
conducted in accordance with good clinical practice
requirements and compliance with the ethical princi-
ples described in the current revision of the Declara-
tion of Helsinki.
INCLUSION/EXCLUSION
CRITERIA
As this study seeks to reﬂect real-world clinical prac-
tice, patients may be enrolled if they are being man-
aged or treated for PBC, regardless of which treatment
they are receiving. The diagnosis of PBC is made by
the treating physician to reﬂect real-world practice.
Patients are excluded if they are unable to provide writ-
ten informed consent and/or are simultaneously
enrolled in another prospective registry or clinical trial
or study where PBC treatment outcomes are reported
TABLE 1. DEFINITIONS OF BIOCHEMICAL RESPONSE TO UDCA IN PBC
Criteria Definition
Paris I ALP <3 times ULN, aspartate aminotransferase <2 times ULN, and bilirubin 1 mg/dL after 1 year of UDCA
Barcelona ALP decline of >40% toward baseline value or a normal level after 1 year of UDCA treatment
Rotterdam Normalization of bilirubin and albumin concentrations after treatment with UDCA when one or both parameters were abnormal
before treatment or normal bilirubin or albumin concentrations after treatment when both were abnormal at entry
Paris II ALP and aspartate aminotransferase 1.5 times ULN and normal total bilirubin after 1 year of UDCA therapy
Toronto ALP <1.67 times ULN at 2 years of UDCA therapy
GLOBE PBC Age (years) at initiation of UDCA therapy and total bilirubin, alkaline phosphatase level, albumin, and platelets after 1 year of
therapy are compiled to produce an age and sex-matched score. Globe score >0.3 indicates shortened survival free of liver
transplantation compared to controls.
United Kingdom-PBC Total bilirubin, alanine transaminase/aspartate transaminase, and ALP compared to ULN and serum albumin and platelet count
compared to LLN after at least 12 months of UDCA therapy
Abbreviations: LLN, lower limit of normal; ULN, upper limit of normal.
LEVY ET AL. HEPATOLOGY COMMUNICATIONS, May 2018
486
(except where approved or conducted as an adjunct
project of TARGET-PBC).
To improve our ability to detect clinically relevant
events during the 5-year follow-up period and given
that UDCA has been well studied for decades, an
amendment to the study protocol for targeted enroll-
ment was generated to enrich the study population
with UDCA nonresponders and UDCA-intolerant
patients. This strategy allows us to focus on at-risk
patients and to better understand how new therapies
impact outcomes in PBC.
OUTCOMES OF INTEREST
The primary and secondary aims of the study are
listed in Table 2 and include mainly the evaluation of
effectiveness and safety of various treatment regimens
for PBC. This includes use of off-label medications,
such as fenoﬁbrate, and immunosuppressants, such as
budesonide, mycophenolate mofetil, and tacrolimus.
Additional outcomes of interest include disease
progression (i.e., worsening of ﬁbrosis, incident cirrho-
sis, and cirrhosis decompensation events) and medica-
tion effectiveness in special populations (Table 3)
unlikely to be represented in clinical trials. With
respect to comorbidities, we are particularly interested
in studying the impact of associated autoimmune
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FIG. 1. US map of TARGET-PBC participating sites at the moment of manuscript submission. Green, sites that are actively enroll-
ing patients; yellow, sites in start-up stage; blue, sites in feasibility stage.
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TABLE 2. PRIMARY AND SECONDARY AIMS OF
TARGET-PBC
Primary aims  Evaluate PBC treatment regimens being used
in clinical practice
 Examine outcomes in populations underrepresented
in phase III clinical trials
 Examine biochemical response to various
treatment regimens and its association with
long-term outcomes
 Estimate adverse event frequency and severity
and describe management practices
Secondary aims  Describe response rates and safety in special
populations
 Determine safety and efficacy of unapproved regimens
 Evaluate drug–drug interactions
 Evaluate health outcomes and durability of clinical
response
 Evaluate patient reported outcomes measures
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hepatitis (overlap syndrome autoimmune hepatitis-
PBC), other autoimmune diseases, and metabolic syn-
drome on the course of PBC. With our data set, we
will also be able to evaluate the impact of sex, race/
ethnicity, and comorbidities on the progression of PBC.
STUDY PROCEDURES
After informed consent is obtained, redacted
medical records for the previous 3 years are gathered.
Structured and unstructured data are then extracted for
medication use, comorbid conditions, imaging tests,
endoscopic procedures, surgeries, and pathology.
Patients who have consented to complete optional
patient reported outcome (PRO) surveys will do so
every 6 months as outlined below (Table 4). Patients
who have consented to be part of the Biorepository
Specimen Bank will have blood collected during regu-
lar clinical blood work for DNA/RNA and serum
analysis every 12 months 6 6 months as outlined
below. Patients can schedule the blood draw at their
convenience, or this may be combined with a routine
doctor’s appointment. There are no study-mandated
interventions or assessments planned. Clinical data will
be accrued over 5 years during routine clinical encoun-
ters. At month 60, participation in the study will be
terminated. Patients who at any point sign a consent
for an outside clinical trial or other registry will be
ﬂagged and will temporarily discontinue participation
in TARGET-PBC.
OPTIONAL PRO SURVEYS
Patients enrolled in TARGET-PBC are invited to
complete PRO surveys every 6 months by phone or a
web-based system. These surveys are optional and
participation in this component does not affect partici-
pation in the main study. The PROs include the
PBC-40,(12) 5-D pruritis scale (5-D itch),(13) and the
Patient Reported Outcome Measurement Information
System Fatigue–Short Form 8a.(14) Additional PROs
may be added throughout the course of the study. Any
additional PROs will be approved by the IRB prior to
participant completion.
OPTIONAL BIOREPOSITORY
SAMPLES
Blood samples for biomarker and DNA/RNA assays
and serum analysis are collected on a voluntary basis,
and participation in this component of the study does
not affect participation in the main study. These sam-
ples are shipped to a central repository for storage to
use in future analyses and studies as detailed below.
In order to begin participation in the Biorepository
Specimen Bank, patients must provide an additional
consent. Obtaining samples for biomarkers or DNA/
RNA at a given site will be contingent on that site’s
TABLE 3. SPECIAL POPULATIONS EVALUATED IN
TARGET-PBC
 Patients with cirrhosis, compensated or not
 Patients before and after liver transplant
 Patients with comorbidities
 Patients with other coexisting liver disease, such as autoimmune
hepatitis (overlap syndrome), nonalcoholic fatty liver disease,
alcoholic liver disease, or viral hepatitis
 Patients using concomitant medications that were excluded in clinical
trials, such as various immunosuppressants, biologicals, fibrates, and
corticosteroids
TABLE 4. TABLE OF PROCEDURES FOR TARGET-PBC
Activity
Screening/
Enrollment Visit* Follow-Up
Year 1 Year 2 Year 3 Year 4 Year 5
Month 0§ 3, 6, 9 12 18 24 30 36 42 48 54 60
Informed consent X
Inclusion/exclusion X
Blood sample collection† X X X X X X
Patient reported outcome surveys‡ X X‡ X X X X X X X X X
Medical records submissionk X§ X X X X X X X X X X
*Study procedures are completed at a regularly scheduled clinic visit.
†Participants will be asked to provide an optional annual blood sample. Blood will be collected during a regular clinic visit approxi-
mately 12 months but not more than 18 months from the previous collection.
‡Participants will be asked to complete optional, web-based patient reported outcome surveys approximately every 6 months.
k3 years of redacted historical records (Month 0) will be submitted following the Screening/Enrollment visit.
§During the follow up period, redacted medical records will be submitted every 3 months during year 1 and every 6 months during
years 2-5. The ﬁrst submission during the follow-up period will be 3 months following the Screening/Enrollment visit. Additional
interim medical records submissions may be requested.
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IRB regulations. Collected samples will be stored
indeﬁnitely. These samples can be used for research
and teaching purposes or for research toward the devel-
opment of new medical products or diagnostic tests
relevant to PBC. Patients receive a small monetary
incentive if they choose to participate in this portion of
the study.
DATA MANAGEMENT
All data are collected, processed, transmitted, and
stored by an electronic data capture system. TARGET
PharmaSolutions abstractors are personally trained by
the TARGET-PBC Steering Committee Chair; they
review and abstract entered data. Later, clinical moni-
tors review and ensure that these data correspond with
data in the source documents (i.e., redacted medical
records). Data management activities, such as query
management and coding of adverse event terms, are
performed by TARGET PharmaSolutions or its des-
ignee. Both abstractors and monitors are well trained
and can email the Chair or members of the Steering
Committee with speciﬁc questions at any time. This
system of multiple levels of data control promotes
transparency and accuracy.
Speciﬁc efforts are made to investigate and docu-
ment the reasons for missing data, including lost-to-
follow-up data. The appropriate analysis strategy for
managing incomplete data depends on the nature of
the particular analysis of interest and on the nature of
the underlying mechanisms responsible for the occur-
rence of missing values. In some cases, the pattern of
missing values is itself of interest; in other cases, estab-
lished likelihood-maximization methods, analogous to
those used in human immunodeﬁciency virus observa-
tional studies,(15) are used to manage missing data
mechanisms that are noninformative and can be legiti-
mately ignored.
PLANS FOR STATISTICAL
ANALYSIS
This longitudinal observational study will use ana-
lytical methods to characterize primary and secondary
aims. Outcomes of interest based on the research aims
will be collected for each participant. Baseline charac-
teristics of each participant will be collected to provide
covariate-adjusted proportions, means, and rates (as
needed), with corresponding measures of variability.
Longitudinal analyses of the experiences of the partici-
pants will involve event incidence rates, risk factors,
adverse events, and relative risk-type estimates. There
will be estimates to investigate and document any
incomplete data. Auxiliary analyses will be conducted
to guide levels of conﬁdence in the main results.
Discussion
TARGET-PBC is a longitudinal observational
study conducted in both academic and community
sites to create a real-world view of the natural history
and clinical management of PBC in patients who are
diagnosed and treated in this setting. Importantly, data
generated from this study will address gaps in our
knowledge of the clinical effectiveness of PBC-related
interventions and provide valuable postmarketing sur-
veillance of new PBC therapies. Special populations
that might be excluded or underrepresented in clinical
trials will be represented in this study, including ethnic
minorities, patients with advanced cirrhosis, and those
with an overlap syndrome with autoimmune hepatitis.
Furthermore, most natural history data are limited to
tertiary centers or large administrative database studies;
TARGET-PBC allows a broader inclusion of patients
being managed for PBC rather than those assumed to
have PBC through administrative billing codes.
With this setup, TARGET-PBC seeks to under-
stand the natural history of PBC and to describe PBC
management techniques as they exist in a real-world
setting. As regulatory authorities, such as the FDA,
approve new medications, this data set can serve to
monitor for drug-related adverse events and the impact
of new interventions on liver, autoimmune, and neo-
plastic outcomes. TARGET-PBC is based on the
model used for hepatitis C virus (HCV)-TARGET, a
cooperative academic consortium that guides safe and
effective use of direct-acting antivirals approved for the
treatment of chronic HCV infection and which has
been extremely successful providing real-world safety
and effectiveness data for newer therapies.(16) While
there are only two drugs currently approved for PBC
(UDCA and OCA), several other promising therapies
are currently under investigation, and TARGET-PBC
will capture these new therapies as they enter the
market.
Given the very long clinical course of PBC, clinical
trials are often unable to ascertain hard endpoints, such
as clinical decompensation, need for liver transplant, or
death, and instead assess efﬁcacy through impact on
surrogate endpoints. That was the case for OCA,
which was granted accelerated approval by the FDA
HEPATOLOGY COMMUNICATIONS, Vol. 2, No. 5, 2018 LEVY ET AL.
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based on improvement in serum ALP. For this reason,
continued approval of OCA is dependent on conﬁrma-
tion of the beneﬁcial effects in subsequent studies eval-
uating its efﬁcacy in improving clinically relevant
endpoints.(10) Therefore, a phase 3b study of OCA
evaluating clinical outcomes in patients with primary
biliary cholangitis (COBALT) is in progress and
is expecting to enroll 350 patients and have follow-up
for approximately 8 years to answer this question.
TARGET-PBC is designed to assess similar end-
points in a large population of patients with PBC in
real life, which will complement this ongoing study.
Furthermore, beyond measuring clinical effectiveness,
postmarketing, real-world, rigorous, observational
studies are important for collecting and interpreting
PROs.(17) In addition, TARGET-PBC encourages
interactions between all stakeholders, including the
investigators, patient representatives, industry partners,
and regulatory authorities. Any stakeholder may submit
a scientiﬁc query to the steering committee, and this will
trigger proper database analyses and data generation,
thus promoting scientiﬁc output and perhaps accelerat-
ing postmarketing safety and efﬁcacy evaluations.
As with other methodology papers, the beneﬁts of
this one are to promote prospective registration,
increase collaboration, decrease duplication of research
efforts, boost recruitment and referrals, and allow for
published medical searches and systematic reviews to
identify all relevant work. The TARGET-PBC study
has prespeciﬁed hypotheses to decrease bias and pro-
mote transparency and accuracy in research.
In summary, TARGET-PBC is using standardized
data collection practices, study data monitoring, and a
comprehensive observational protocol to increase the
efﬁciency of performing clinical research while ensur-
ing collection of detailed critical safety and effective-
ness data on prescribed PBC therapies. TARGET-
PBC engages community and academic practice
providers as partners in the research to ensure rapid
translation of research ﬁndings into improvement in
health care quality and outcomes. Furthermore, the
availability of an established cohesive research network
allows nimble responses to investigations of new treat-
ment paradigms with existing agents as well as future
generations of PBC therapies.
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